Onetouch Ping Diabetes System Gets FDA Approval:The two Johnson & Johnson companies Animas, an insulin pump manufacturer, and Onetouch, a well-known producer of glucose meters and strips, have teamed up to produce the Onetouch Ping, which received FDA Clearance today. The Ping is the first glucose-meter and insulin pump combo that employs wireless communication.
OneTouch Ping provides patients the advanced insulin pump technology from Animas plus the OneTouch blood glucose technology they trust, put together into a system that offers the discretion, convenience and option of remote insulin dosing," said Juan Frias, M.D., Chief Medical Officer and Vice President of Medical Affairs, Animas Corporation. “People using OneTouch Ping will no longer have to access their pump to deliver a bolus, ultimately making life with diabetes a little easier.”
Silent Corticotropinoma:
Pawlikowski M, Kunert-Radek J, Radek M.
Departments of Neuroendocrinology and Clinical Endocrinology, Chair of Endocrinology and Department of Neurosurgery and Surgery of Peripheral Nerves, Medical University of Lodz, Poland.
OBJECTIVES: The aim of the study was to evaluate the ACTH-immunopositive pituitary adenomas, especially those without manifestation of Cushing's disease....
CONCLUSIONS: (i) "Silent" corticotropinomas are rather frequent. (ii) This adenoma type should be considered as aggressive. (iii) It is hypothetized that -like in Nelson's syndrome - the lack of hypercortisolism or even presence of hypocortisolism favorizes the exaggerated growth of tumoral corticotrophs.
Sarcoidosis and Obesity:
INTRODUCTION: Polypliagia and morbid obesity appears in patients with sarcoidosis may be signs of neurosarcoidosis in the medial hypothalmus where satiety center is located. It is estimated that about 1% of all patients with sarcoidosis may have sarcoidosis of the hypothalamus. It is of utmost importance to diagnose and treat hypothalamic sarcoidosis as early as possible......
No comments:
Post a Comment